It is 76% effective in preventing symptomatic COVID-19 instead of the 79% previously claimed
According to the Observer, AstraZeneca has recalculated the study data on the effectiveness of its vaccine and concluded that it is 76% effective in preventing symptomatic COVID-19 instead of the 79% claimed earlier this week.
“The recalculation of the data had to be carried out after an independent panel accused the pharmaceutical company of collecting data in order to promote the vaccine”, – the AP reports.
The group said in a sharp letter to the company and US health chiefs that AstraZeneca had failed to take into account some cases of coronavirus infection in its analysis, which could undermine confidence in the vaccine. It is noted that such disputes usually remain confidential, but in this case the National Institutes of Health publicly called on AstraZeneca to correct inaccuracies in the study.